You are here

Our science / Clinical Trials / Find a Trial / NCT00137293

Study Evaluating GAP-486 in Heart Rhythm

Back to Search Print Save as PDF Bookmark Trial

NCT00137293

Last updated on May 11, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
San Francisco, California, 94143 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Arrhythmia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients undergoing an electrophysiology study for evaluation of heart rhythm.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients with uncontrolled blood pressure

- Patients with certain cardiac risk factors

- Patients with significant kidney or liver problems

NCT00137293
Pfizer
Terminated
Study Evaluating GAP-486 in Heart Rhythm

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Arrhythmia
Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease
NCT00137332
All Genders
18+
Years
Multiple Sites
Arrhythmia
Study Evaluating GAP-486 in Heart Rhythm
NCT00137293
All Genders
18+
Years
Multiple Sites
Arrhythmias
Study Evaluating GAP-486 in Non-Sustained Ventricular Tachycardia
NCT00124891
All Genders
18+
Years
Multiple Sites
Arrhythmia
Atorvastatin For The Reduction Of Ventricular Arrhythmias
NCT00457340
All Genders
18+
Years
Multiple Sites
Study Evaluating GAP-486 in Heart Rhythm
A Study to Characterize the Acute Electrophysiologic Properties, Safety and Tolerability of GAP-486
The purpose of this study is to learn the effects of a test drug on heart rhythm, and to provide additional data to see if the test drug is well tolerated and safe.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Arrhythmia
  • Drug: GAP-486 (ZP-123)
  • Drug: 0.9% Sodium Chloride, USP
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
30
October 2006
Not Provided

Inclusion Criteria:

  • Patients undergoing an electrophysiology study for evaluation of heart rhythm.

Exclusion Criteria:

  • Patients with uncontrolled blood pressure
  • Patients with certain cardiac risk factors
  • Patients with significant kidney or liver problems
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada,   United States
 
 
NCT00137293
3163K1-201
Not Provided
Not Provided
Not Provided
Not Provided
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
December 2007

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now